Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human Calreticulin Anticorps:
anti-Mouse (Murine) Calreticulin Anticorps:
anti-Rat (Rattus) Calreticulin Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Cow (Bovine) Polyclonal Calreticulin Primary Antibody pour BP, DB - ABIN153063
Placantonakis, Cicirata, Welsh: A dominant negative mutation of neuronal connexin 36 that blocks intercellular permeability. dans Brain research. Molecular brain research 2002
Show all 20 Pubmed References
Chicken Polyclonal Calreticulin Primary Antibody pour ICC, FACS - ABIN361835
Antoniou, Ford, Pilley, Blake, Powis: Interactions formed by individually expressed TAP1 and TAP2 polypeptide subunits. dans Immunology 2002
Show all 19 Pubmed References
Human Monoclonal Calreticulin Primary Antibody pour IF, WB - ABIN968753
Ito, Seyama, Kubota: Calreticulin is directly involved in anti-alpha3 integrin antibody-mediated secretion and activation of matrix metalloprotease-2. dans Biochemical and biophysical research communications 2001
Show all 4 Pubmed References
Human Monoclonal Calreticulin Primary Antibody pour IF, WB - ABIN968752
Mazzarella, Gold, Cunningham, Green: Determination of the sequence of an expressible cDNA clone encoding ERp60/calregulin by the use of a novel nested set method. dans Gene 1992
Show all 4 Pubmed References
Human Polyclonal Calreticulin Primary Antibody pour ICC, IF - ABIN269297
Leslie, Watkins, Kim, Brouwer: Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. dans The Journal of pharmacology and experimental therapeutics 2007
Show all 4 Pubmed References
Human Polyclonal Calreticulin Primary Antibody pour WB - ABIN2801959
McCauliffe, Lux, Lieu, Sanz, Hanke, Newkirk, Bachinski, Itoh, Siciliano, Reichlin: Molecular cloning, expression, and chromosome 19 localization of a human Ro/SS-A autoantigen. dans The Journal of clinical investigation 1990
Show all 4 Pubmed References
Human Polyclonal Calreticulin Primary Antibody pour ELISA, WB - ABIN969575
Harada, Okiyoneda, Hashimoto, Ueno, Nakamura, Yamahira, Sugahara, Shuto, Wada, Suico, Kai: Calreticulin negatively regulates the cell surface expression of cystic fibrosis transmembrane conductance regulator. dans The Journal of biological chemistry 2006
Show all 3 Pubmed References
Human Polyclonal Calreticulin Primary Antibody pour FACS, IF (p) - ABIN759731
Chen, Wu, Xu, Xu: Calreticulin Binds to Fas Ligand and Inhibits Neuronal Cell Apoptosis Induced by Ischemia-Reperfusion Injury. dans BioMed research international 2015
Show all 3 Pubmed References
Human Monoclonal Calreticulin Primary Antibody pour IF, IHC - ABIN965739
Tan, Chen, Li, Mabuchi, Bouvier: The calcium- and zinc-responsive regions of calreticulin reside strictly in the N-/C-domain. dans Biochimica et biophysica acta 2006
Show all 2 Pubmed References
Human Monoclonal Calreticulin Primary Antibody pour IHC, WB - ABIN222922
Mansilla, da Costa, Wang, Kruhøffer, Lewin, Orntoft, Coleman, Birkenkamp-Demtröder: Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer. dans Journal of molecular medicine (Berlin, Germany) 2008
these results reveal proteome alterations in MPN (Montrer PRSS27 Anticorps) granulocytes depending on the phenotype and genotype of patients, highlighting new oncogenic mechanisms associated with JAK2 (Montrer JAK2 Anticorps) mutations and overexpression of calreticulin
CALR mutation is associated with Essential thrombocythemia.
the CALR-mutant stem cell would achieve clonal dominance much faster than the JAK2 (Montrer JAK2 Anticorps)-mutant one and confirm the model initially proposed in which the clonal evolution of CALR-mutant MPN (Montrer PRSS27 Anticorps) appears to be mainly associated with a progressive expansion of a mutant heterozygous clone that eventually becomes fully dominant in the bone marrow.
The present study detected expression of CRT (Montrer SLC6A8 Anticorps) in patients with osteosarcoma , in the non-metastasis group compared with the metastasis group, and in the chemotherapy group compared with the non-chemotherapy group. CONCLUSIONS: These results could indicate a brand-new biological marker which may be applied to estimate the features and prognosis of osteosarcoma.
in molecularly annotated ET patients at diagnosis, JAK2 (Montrer JAK2 Anticorps)-V617F patients have more circulating microparticles and higher MP-associated procoagulant activities than CALR-mutated and TN ET patients.
results suggest that CALR exon 9 mutations hold promise as targets for cancer immune therapies; for example as targets for vaccines or adoptive cell therapies. In order to formally establish that the CALR mutations act as tumor antigens for immunotherapy, we are currently working to establish specific T-cell clones to show that such clones recognize target cells that endogenously express mutated CALR
Report PCR clamping technique for detection of type 1 and type 2 mutations in CALR gene in myeloproliferative neoplasms.
Late-stage inhibition of autophagy enhances calreticulin surface exposure in colonic tumor cells.
JAK2 (Montrer JAK2 Anticorps) and CALR mutations have roles in patients with essential thrombocythemia
Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.
Calreticulin is required for TGF-beta (Montrer TGFB1 Anticorps) mediated epithelial-mesenchymal transition and cardiomyogenesis from mESCs.
CALR mutation analysis can thus be a useful additional diagnostic tool to achieve an accurate diagnosis for patients with ET who lack JAK2V617F and MPLW515 mutations
CRT (Montrer SLC6A8 Anticorps) inhibition significantly blunted APN's anti-oxidative action (evidenced by gp91(phox (Montrer CYBB Anticorps)) expression and superoxide generation). However, CRT (Montrer SLC6A8 Anticorps) inhibition did not attenuate AMPK (Montrer PRKAA1 Anticorps) phosphorylation by APN (Montrer ANPEP Anticorps) administration in NCM (Montrer CWC22 Anticorps). Therefore, these novel findings strongly indicate that APN (Montrer ANPEP Anticorps) exerts cardioprotective effects against I/R injury partially via CRT (Montrer SLC6A8 Anticorps) mediated anti-apoptotic and anti-oxidative actions.
we show that the homologous mouse CALR del52, ins5 and del61 mutants also activate thrombopoietin receptor (Montrer MPL Anticorps) signaling via JAK (Montrer JAK3 Anticorps)-STAT (Montrer STAT1 Anticorps) pathway
study provides a model showing that the C-terminal of mutant CALR activated JAK (Montrer JAK3 Anticorps)-STAT (Montrer STAT1 Anticorps) signaling specifically downstream of MPL (Montrer MPL Anticorps) and may have a central role in CALR-induced myeloproliferative neoplasms
the results of this investigation provide the first molecular insights into the phospholipid binding site of calreticulin as a key anchor point for the cell surface expression of calreticulin on apoptotic cells
a profound impairment in calreticulin function when its lectin site was inactivated. Remarkably, inactivation of the polypeptide binding site had little impact. These findings indicate that the lectin-based mode of client interaction is the predominant contributor to the chaperone functions of calreticulin within the endoplasmic reticulum.
This essential role of calreticulin in nucleocytoplasmic communication competency ties its regulatory action with proficiency of cardiac myofibrillogenesis essential for proper cardiac development.
Study provides evidence that chronic stress activates calreticulin and might be one of the pathological mechanisms underlying the motor coordination and motor learning dysfunctions seen in social defeat mice.
This study for the first time revealed that increased CRT (Montrer SLC6A8 Anticorps) inhibited Fas (Montrer FAS Anticorps)/FasL (Montrer FASL Anticorps)-mediated neuronal cell apoptosis during the early stage of ischemic stroke, suggesting it to be a potential protector activated soon after ischemia-reperfusion injury
These findings showed that mutant CALR activates jak (Montrer JAK3 Anticorps)-stat (Montrer STAT1 Anticorps) signaling through an mpl (Montrer MPL Anticorps)-dependent mechanism to mediate pathogenic thrombopoiesis in zebrafish, and illustrated that the signaling machinery related to mutant CALR tumorigenesis are conserved between human and zebrafish.
Calreticulin plays a key role in olfactory system function, possibly by establishing its overall sensitivity to odorants.
Calreticulin mediates hypersensitivity to diethylether and resistance to isoflurane in association with low expression of the gene.
These results collectively indicate that calreticulin is the first molecule to be identified as a marker for phagocytosis of apoptotic cells by Drosophila phagocytes
Calreticulin is confined to subplasmalemmal vesicles partially overlapping with cortical granule contents. Its exocytosis after the oocyte activation seems to participate in the membrane block to polyspermy in pigs.
Calreticulin was widely expressed in pig tissues and its transcripts were downregulated during maturation, especially at 44 hr, and were undetectable at the blastocyst stage.
the lectin site of CRT is the main target for gentamicin binding
These findings suggest that protein kinase C (Montrer PKC Anticorps) is involved in the regulation of CRT function.
Calreticulin is a multifunctional protein that acts as a major Ca(2+)-binding (storage) protein in the lumen of the endoplasmic reticulum. It is also found in the nucleus, suggesting that it may have a role in transcription regulation. Calreticulin binds to the synthetic peptide KLGFFKR, which is almost identical to an amino acid sequence in the DNA-binding domain of the superfamily of nuclear receptors. Calreticulin binds to antibodies in certain sera of systemic lupus and Sjogren patients which contain anti-Ro/SSA antibodies, it is highly conserved among species, and it is located in the endoplasmic and sarcoplasmic reticulum where it may bind calcium. The amino terminus of calreticulin interacts with the DNA-binding domain of the glucocorticoid receptor and prevents the receptor from binding to its specific glucocorticoid response element. Calreticulin can inhibit the binding of androgen receptor to its hormone-responsive DNA element and can inhibit androgen receptor and retinoic acid receptor transcriptional activities in vivo, as well as retinoic acid-induced neuronal differentiation. Thus, calreticulin can act as an important modulator of the regulation of gene transcription by nuclear hormone receptors. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin but calreticulin is not a Ro/SS-A antigen. Earlier papers referred to calreticulin as an Ro/SS-A antigen but this was later disproven. Increased autoantibody titer against human calreticulin is found in infants with complete congenital heart block of both the IgG and IgM classes.
, Sicca syndrome antigen A (autoantigen Ro; calreticulin)
, endoplasmic reticulum resident protein 60
, pot pourri
, calcium-binding protein 3
, ER-resident chaperone calreticulin
, Endoplasmic reticulum resident protein 60
, calreticulin, like 2